Zolgensma
onasemnogene abeparvovec
Muscular Atrophy, Spinal
Date of authorisation:
Revision: 15
Last updated:
MedicineHumanAuthorised
Upstaza
eladocagene exuparvovec
Amino Acid Metabolism, Inborn Errors
Date of authorisation:
Revision: 7
Last updated:
MedicineHumanAuthorised
Health technology assessment bodies

The European Medicines Agency (EMA) is working closely with health technology assessment (HTA) bodies. Regional and national HTA bodies provide recommendations on medicines and other health technologies that can be financed or reimbursed by the healthcare system in a particular European Union (EU) Member State or region.

Last updated:
HumanAdvanced therapies
Casgevy
Exagamglogene autotemcel
beta-Thalassemia
Anemia, Sickle Cell
Date of authorisation:
Revision: 1
Last updated:
MedicineHumanAuthorised
Kymriah
tisagenlecleucel
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
Lymphoma, Large B-Cell, Diffuse
Date of authorisation:
Revision: 16
Last updated:
MedicineHumanAuthorised
Committee for Advanced Therapies (CAT): 17-19 January 2024

The Committee for Advanced Therapies (CAT) is the committee that is responsible for assessing the quality, safety and efficacy of advanced-therapy medicines.

European Medicines Agency, Amsterdam, the Netherlands
Start date: 17 January 2024
End date: 19 January 2024
EventHumanAdvanced therapiesInnovation
Yescarta
axicabtagene ciloleucel
Lymphoma, Follicular
Lymphoma, Large B-Cell, Diffuse
Date of authorisation:
Revision: 15
Last updated:
MedicineHumanAuthorised
Hemgenix
etranacogene dezaparvovec
Hemophilia B
Date of authorisation:
Revision: 3
Last updated:
MedicineHumanAuthorised